Enamine/Bienta is participating in EU Horizon 2020 grant-funded program“Peptidomimetics with photocontrolled biological activity” headed by research teams from Karlsruhe Institute of Technology, University of Cambridge, Latvian Institute of Organic Synthesis and Enamine. Bienta’s preclinical biology team is supporting characterization of a photodynamic cancer drug candidate by DMPK and animal efficacy studies. In April 2016, Bienta’s researchers co-authored a prestigious paper on the subject (Babii et al., Angew.Chem.Int.Ed., 2016; 55: 5493-6).